Kenichi Inoue

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 8

Top Topics

Prognostic Factors

Metastatic Breast Cancer

Top Venues

Investigational new drugs

Patient related outcome measures

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Ian E Krop, Norikazu Masuda, Toru Mukohara, Shunji Takahashi, Takahiro Nakayama, Kenichi Inoue, Hiroji Iwata, Yutaka Yamamoto, Ricardo H Alvarez, Tatsuya Toyama, Masato Takahashi, Akihiko Osaki, Shigehira Saji, Yasuaki Sagara, Joyce O'Shaughnessy, Shoichi Ohwada, Kumiko Koyama, Tatsuya Inoue, Li Li, Parul Patel, Joseph Mostillo, Yoshimi Tanaka, David W Sternberg, Dalila Sellami, Kan Yonemori
Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3-Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3-Expressing Metastatic Breast Cancer: A Multicenter, Phase I/II Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Haruru Kotani, Norikazu Masuda, Toshinari Yamashita, Yoichi Naito, Tetsuhiko Taira, Kenichi Inoue, Masato Takahashi, Kan Yonemori, Shigeyuki Toyoizumi, Yuko Mori, Takashi Nagasawa, Natsuki Hori, Hiroji Iwata
Efficacy and safety of talazoparib in Japanese patients with germline BRCA-mutated locally advanced or metastatic breast cancer: results of the phase 1 dose-expansion study. Breast cancer (Tokyo, Japan) 29 (6) (2022)
Rieneke T Lugtenberg, Adrian A Kaptein, Ayako Matsuda, Kenichi Inoue, Michael Murray, Kunihiko Kobayashi, Kaoru Kubota, Hein Putter, Kazue Yamaoka, Johannes W R Nortier, Judith R Kroep, Maarten J Fischer
Perceptions of Japanese and Dutch women with early breast cancer about monitoring their quality of life. Journal of psychosocial oncology (2021)
Manja Vollmann, Ayako Matsuda, Judith R Kroep, Kunihiko Kobayashi, Kaoru Kubota, Kenichi Inoue, Kazue Yamaoka, Hein Putter, Rajen Ramai, Johannes W R Nortier, Maarten J Fischer, Adrian A Kaptein
Illness Perceptions and Quality of Life in Patients with Non-Small-Cell Lung Cancer: A 3-Month Follow-Up Pilot Study. Patient related outcome measures 11 (2020)
Kenichi Inoue, Masato Takahashi, Hirofumi Mukai, Takashi Yamanaka, Chiyomi Egawa, Yukinori Sakata, Hiroki Ikezawa, Toshiyuki Matsuoka, Junji Tsurutani
Effectiveness and safety of eribulin in Japanese patients with HER2-negative, advanced breast cancer: a 2-year post-marketing observational study in a real-world setting. Investigational new drugs 38 (5) (2020)
Kenichi Inoue, Shigenori E Nagai, Tsuyoshi Saito, Takashi Sakurai, Kei Kimizuka, Hirofumi Yamada, Toru Kuroda, Satoshi Hata, Yasuo Yamazaki, Masato Kojima, Kazushige Futsuhara, null null
TS-1 add-on therapy in Japanese patients with triple-negative breast cancer after neoadjuvant or adjuvant chemotherapy: a feasibility study. Investigational new drugs 38 (1) (2019)
Kenichi Inoue, Jun Ninomiya, Tsuyoshi Saito, Katsuhiko Okubo, Takashi Nakakuma, Hirofumi Yamada, Kei Kimizuka, Tohru Higuchi, null null
Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm clinical trial. Investigational new drugs 37 (3) (2019)
Kenichi Inoue, Jun Ninomiya, Tsuyoshi Saito, Kei Kimizuka, Masafumi Kurosumi
Induction therapy with paclitaxel and bevacizumab followed by switch maintenance therapy with eribulin in Japanese patients with HER2-negative metastatic breast cancer: a multicenter, collaborative, open-label, phase II clinical study for the SBCCSG 35 investigators. BMC cancer 18 (1) (2018)